Lung-selective cytochrome P450 expression is well recognized; however, little is known regarding regulatory mechanisms. To address this knowledge gap, transient expression of CYP4B1/luciferase constructs was used to identify a proximal, positively acting regulatory element, position ؊139 to ؊45, that functioned in all cells examined; a negatively acting element, position ؊457 to ؊216, that only functioned in HepG2 hepatoblastoma cells; and a distal, positively acting element, position ؊1087 to ؊1008, that functioned in A549 or BEAS-2B lung-derived cells but not HepG2 cells or 293 kidney-derived cells. Competitive electrophoretic mobility shift assays further localized specific A549, but not HepG2, nuclear protein binding to two sites within the distal element, CYP4B1 position ؊1052 to ؊1042 and ؊1026 to ؊1008. Several potential lung-selective transcription factor recognition sequences were identified within these elements. However, attempts to identify specific factor(s) were unsuccessful. In contrast, in vitro DNA/ protein binding assays combined with transient expression and mutagenesis studies identified two functional Sephadex protein/ Krü ppel-like factor families of transcription factor sites within the proximal element (position ؊118 to ؊114 and position ؊77 to ؊73) that bound both Sephadex protein 1 (Sp1) and Sephadex protein 3 (Sp3) in vitro. Furthermore, Sp1-dependent synergistic regulation was observed in A549 cells involving the proximal and distal regulatory elements. Chromatin immunoprecipitation assays demonstrated binding of neither Sp1 nor Sp3 to the CYP4B1 proximal element in human liver tissue, whereas selective Sp1 binding was observed in human lung tissue. Thus, the composite findings are consistent with both the proximal Sp1 elements and the distal regulatory element acting to synergistically control CYP4B1 lungselective expression.
The cytochrome P450-dependent monooxygenases consist of a large family of heme proteins that catalyze the oxidative metabolism of both endogenous and exogenous compounds, often facilitating their elimination from the organism. Depending on the substrate, however, these same reactions can lead to reactive intermediates and contribute to a pathological response (Guengerich, 1993; Nebert and Russell, 2002) . Although the liver possesses the highest amount of cytochrome P450 metabolic activity, the lung represents a primary portal to the body and as such, is an important exposure site to many inhaled environmental protoxicants and procarcinogens (Dahl and Lewis, 1993) . As one might expect, lung tissue also can activate several procarcinogens and protoxicants, contributing to the etiology of cancer and other toxic outcomes (Ding and Kaminsky, 2003) . Gaining a better understanding of mechanisms controlling the selective expression of pulmonary cytochrome P450 enzymes will be critical to fully appreciating their role in pulmonary disease.
Several cytochrome P450 enzymes are selectively expressed in the lung, including CYP2A13, CYP2F1, CYP2S1, CYP3A5, and CYP4B1. Recent studies have begun to reveal mechanisms controlling the induction of pulmonary CYP3A5 by glucocorticoids (Hukkanen et al., 2003) and CYP2S1 by 2,3,7,8-tetrachlorodibenzo-pdioxin (Rivera et al., 2002) . However, there is a paucity of knowledge regarding constitutive lung-selective regulatory mechanisms.
In animal models, CYP4B1 bioactivates several protoxicants and procarcinogens, including 2-aminoanthracene (Smith et al., 1995) , 2-aminofluorene (Vanderslice et al., 1985) , and valproic acid (Rettie et al., 1995) . Combined with its lung-selective expression pattern, such observations resulted in considerable interest in CYP4B1. Yet, the activity and function of human CYP4B1 is controversial. Interindividual differences in CYP4B1 expression have been associated with bladder cancer susceptibility (Imaoka et al., 2000) , and elevated CYP4B1 mRNA was demonstrated in lung carcinoma versus normal lung tissue (Czerwinski et al., 1994) . Imaoka et al. (2001) also demonstrated elevated lauric acid -hydroxylase and 2-aminofluorene-dependent umu gene expression using microsomes from human CYP4B1 transgenic mice that were inhibited by a CYP4B1 antibody. Similar activities also were observed using a CYP4B1-NADPH cytochrome P450 oxidoreductase fusion protein expressed in yeast. In contrast, Zheng et al. (2003) reported that human CYP4B1 does not appear to be an active enzyme due to a unique amino acid substitution in the meander region. Irrespective of this controversy, CYP4B1 mRNA is detectable in lung. Thus, this system remains a viable model to better understand molecular mechanisms controlling cytochrome P450 lung-selective expression and was the focus of this study. position Ϫ139 to ϩ35 directing luciferase expression), and pRNH697 (CYP4B1 position Ϫ45 to ϩ35 directing luciferase expression). Similarly, an internal deletion was prepared using a sense primer that annealed at CYP4B1 position Ϫ217 and contained a nonhomologous 5Ј HinDIII site and the antisense primer described above that annealed downstream of the NcoI site at ϩ35. The resulting amplicon was digested with HinDIII/NcoI and cloned into pRNH686 that had been digested with HinDIII/NcoI, deleting a 492-bp fragment representing CYP4B1 position Ϫ457 to ϩ35. The resulting plasmid, pRNH922, contains CYP4B1 position Ϫ1087 to Ϫ457 spliced to position Ϫ217 to ϩ35 directing luciferase expression.
Cell Culture and Transient Expression. A549 cell lung carcinoma cells were maintained in Dulbecco's modified Eagle's medium/nutrient mixture F-12 containing 10% fetal bovine serum and the antibiotics penicillin (5 U/ml) and streptomycin (50 g/ml). HepG2 hepatoblastoma and 293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics as described by Boucher et al. (1993) . BEAS-2B cells were cultured in LHC-9 medium (Biofluids, Rockvillle, MD) using fibronectin/collagen-precoated flasks per the recommendations of the American Type Culture Collection. For transfection studies, 1 ϫ 10 5 cells were subcultured in each well of a 24-well plate. Twenty-four hours later, the cells were at approximately 80% confluence and were transfected with reporter constructs and, if appropriate, expression vectors, using a mixture of 3 g of Lipofectamine 2000, 0.8 g of test plasmid(s), and 0.2 g of pCMV␤gal. After incubation for 16 h at 37°C, transfection medium (Optimem with 5% fetal bovine serum) was replaced with growth medium and the cells were incubated an additional 48 h. The cells were processed and luciferase assays performed following the manufacturer's recommended instructions. Luciferase activity was normalized to ␤-galactosidase activity to correct for transfection efficiency. At least two separate reporter plasmid preparations were used in two independent transfection assays with each experiment performed in triplicate.
Electrophoretic Mobility Shift Assay (EMSA). HepG2 and A549 nuclear protein extracts were prepared as described by Chodosh (1988) using optimized final KCl extraction concentrations of 400 and 600 mM, respectively. Nuclear protein extracts were assayed for protein content, divided into aliquots, and stored at Ϫ80°C until used. Based on transient expression assays with nested deletion mutants, EMSA probes were prepared using specific PCR primer pairs containing nonhomologous BamH1 recognition sequences on their 5Ј-end. Amplified CYP4B1 sequences included positions Ϫ1087 to Ϫ1008, Ϫ1052 to Ϫ1008, Ϫ216 to Ϫ138, and Ϫ138 to Ϫ46. After digestion of the PCR products with BamH1, the probes were radiolabeled using Klenow DNA polymerase (exonucleaseϪ), unlabeled deoxynucleotides and [␣-32 P]dCTP. EMSA was performed as described by Boucher et al. (1993) , with the exception that DNA/protein binding was performed in 10 mM Hepes-HCl pH 7.9, 75 mM KCl, 0.2 mM EDTA, 0.1 mM dithiothreitol, 5% glycerol, and 0.24 g/ml bovine serum albumin. Each 30-l binding reaction contained 10 g of nuclear protein, 1.5 g poly[d(I-C)], and 0.2 ng (approximately 30,000 dpm) of 32 P-labeled probe. To more finely resolve binding elements within the proximal CYP4B1 promoter, double-stranded oligonucleotides were prepared representing CYP4B1 positions Ϫ142 to Ϫ119, Ϫ128 to Ϫ105, Ϫ112 to Ϫ71, and Ϫ88 to Ϫ61 and used in competitive EMSA at a 25-to 300-fold molar excess over the CYP4B1 position Ϫ138 to Ϫ46 probe. Somewhat similarly, double-stranded oligonucleotides representing CYP4B1 sequences from position Ϫ1068 to Ϫ1008, Ϫ1052 to Ϫ1008, Ϫ1052 to Ϫ1026, and Ϫ1042 to Ϫ1008 were prepared and used in competitive EMSA at a 10-to 100-fold molar excess over the CYP4B1 position Ϫ1052 to Ϫ1008 probe. Finally, double-stranded oligonucleotides representing known or consensus binding sites for the Sp/XKLF family, AP-4, Elk-1, HNF3, and C/EBP (Table 1) were prepared and used in competitive EMSA at a 150-fold molar excess over the CYP4B1 position Ϫ1052 to Ϫ1008 probe. EMSA supershift experiments were performed using Transcruz antibodies (Santa Cruz, CA) or antibody preparations generously donated by other investigators (see above). A549 nuclear extract was incubated for 15 min at 4°C with 0.5 to 1.0 g of antibody either prior to or after the addition of the labeled probe.
Site-Directed Mutagenesis. Mutagenesis was achieved using the QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) as directed by the manufacturer. The mutagenic primers (targeted nucleotides are lower case), 5Ј-GGA GGT TGC TGT CTtt GCC TTA TGG CAC TCA GC-3Ј and 5Ј-TGC TGC TGG CTG CAtt GAG TGG CTA GGG-3Ј, were used with pRNH686 as a template, mutagenizing the Sp/XKLF sites at CYP4B1 position Ϫ118 to Ϫ114 (site 2) from CCGCC to ttGCC and Ϫ77 to Ϫ73 (site 5) from GCAGG to GCAtt, respectively, and generating the following modified reporter constructs: pRNH838 (CYP4B1 Ϫ1087 to ϩ35 directing luciferase expression with site 2 modified), pRNH842 (CYP4B1 Ϫ1087 to ϩ35 directing luciferase expression with site 5 modified), and pRNH843 (CYP4B1 Ϫ1087 to ϩ35 directing luciferase expression with site 2 and site 5 modified). Using the same approach as described above to generate the original deletion construct, the following reporter constructs were prepared: pRNH844 (CYP4B1, Ϫ139 to ϩ35 directing luciferase expression with site 2 modified); pRNH845 (CYP4B1, Ϫ139 to ϩ35 directing luciferase expression with site 5 modified), and pRNH846 (CYP4B, Ϫ139 to ϩ35 directing luciferase expression with site 2 and site 5 modified). In all instances, the nucleotide changes were verified by DNA sequence analysis.
Chromatin Immunoprecipitation. Chromatin immunoprecipitation (ChIP) was performed following the procedure of Shang et al. (2000) with minor modifications. Approximately 200 mg of human lung or liver tissue was pulverized in liquid nitrogen, transferred immediately to a 1% formaldehyde solution at room temperature, and fixed for 15 min. After washing the fixed tissue and resuspension in lysis buffer as described (Shang et al., 2000) , the tissue was sonicated 10 times for 10 s each at a power setting of 6 (maximum setting of 10) using a W-220 ultrasonic processor (Heat-System Ultrasonics, Inc., Plainview, NY). Sonicated samples were centrifuged for 10 min at 16,060g to remove particulate matter. An aliquot was taken for analysis of DNA fragmentation and reserved for use as a positive control during PCR analysis. The remaining sample volumes were divided into three equal parts and adjusted to 1 ml with cold dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and 20 mM Tris-HCl, pH 8.1). To each sample, 50 l of salmon sperm DNA (20 g) and protein A agarose (0.15 mg) (UpState Biotechnology, Lake Placid, NY) was added, and the diluted samples were incubated at 4°C for 2 h with rocking to minimize nonspecific binding. Samples were centrifuged as before, and the supernatant fractions were transferred to new tubes. The samples were incubated overnight with rocking at 4°C along with either Sp1, Sp3, or no antibody (control). After adding 50 l of salmon sperm DNA/protein A agarose (UpState Biotechnology), the samples were incubated for an additional 1 h at 4°C before collecting the protein A-bound antibody-complexed chromatin fragments by centrifugation as before. Supernatant fractions were discarded. The protein A agarose-bound antibody-complexed chromatin fragments were sequentially washed as described. The chromatin was eluted from the complexes by incubating with three sequential 50-l aliquots of elution buffer (50 mM Tris, 1% SDS, and 10 mM EDTA, pH 8.0), which were then pooled. After incubating overnight at 65°C to reverse cross-linking, DNA was purified using a QIAquick PCR purification kit (QIAGEN, Valencia, CA). PCR analysis was carried out using 1 l of the purified DNA, oligonucleotide primers 5Ј-TAC CCC AAA ACC AGG CCC CAG GC-3Ј (CYP4B1 position Ϫ241 to Ϫ219) and 5Ј-GCT GGG ATG CGC TAG AGC CTG C-3Ј (CYP4B1 position Ϫ1 to ϩ20), and Platinum TaqDNA polymerase (Invitrogen).
Data Analysis. Regulatory domains identified through functional assays were examined for putative transcription factor binding sites using the Match program in conjunction with the TRANSFAC Professional V 8.3 database (http://www.biobase.de) (Matys et al., 2003) . Luciferase reporter assay results were assessed using a one-way analysis of variance with a Dunnett's T3 post hoc multiple comparison test (SPSS, Chicago, IL). A value of p Ͻ 0.05 was accepted as a significant difference.
Results

Localization of CYP4B1 Tissue-Selective Regulatory Domains.
To identify functional CYP4B1 regulatory domains, a series of reporter constructs were prepared in which CYP4B1 sequences from position Ϫ2183 to ϩ35, Ϫ1087 to ϩ35, Ϫ457 to ϩ35, Ϫ216 to ϩ35, Ϫ139 to ϩ35, and Ϫ45 to ϩ35 directed luciferase expression. Transient expression of these constructs in A549 lung carcinoma cells ( Fig.  1 ) failed to reveal an increase in promoter activity over background (pGL3Basic) with the Ϫ45 to ϩ35 construct. However, inclusion of CYP4B1 sequences from position Ϫ139 to ϩ35 resulted in a 4-fold increase in reporter activity, suggesting the presence of a proximal positive regulatory domain. An additional 2-fold increase in reporter activity was observed when a more distal domain, CYP4B1 positions Ϫ1087 to Ϫ457, was included in the reporter construct, whereas a significant decrease in activity was seen by extending the included CYP4B1 sequences to position Ϫ2183.
To identify CYP4B1 domains selectively active in lung-derived cells, the same reporter constructs were used to transiently transfect both A549 lung carcinoma and HepG2 hepatocellular carcinoma cells (Fig. 2) , as well as BEAS-2B SV40 large T antigen-immortalized bronchial epithelial and 293 adenovirus 5-transformed kidney cells (data not shown). Consistent with what was observed in Fig. 1 , transient expression of the construct containing CYP4B1 sequences from position Ϫ139 to ϩ35 resulted in a 4-fold increase in A549 cell luciferase activity (Fig. 2B ), whereas a 3-fold increase was observed in HepG2 cells ( Fig. 2A) . Qualitatively similar results were observed in both BEAS-2B and 293 cells (data not shown). Although no further change in luciferase activity was observed in any of the cell lines by including sequences up to position Ϫ216, extending the CYP4B1 sequences to position Ϫ457 resulted in a significant decrease in HepG2 luciferase activity ( Fig. 2A ) but no change in A549 (Fig. 2B) , BEAS-2B, or 293 cells (data not shown). Finally, an additional 2-fold increase in reporter activity was observed when a more distal domain, CYP4B1 position Ϫ1087 to Ϫ457, was included in the reporter construct and used to transfect A549 cells (Fig. 2B ), but no change was observed in HepG2 cells ( Fig. 2A) . Results qualitatively similar to those seen with A549 cells were observed when these same transient expression assays were performed using the human bronchial epithelial cells, BEAS-2B (data not shown). In contrast, when the experiments were repeated in the kidney-derived 293 cells, upregulation was not observed with the CYP4B1 position Ϫ1087 to Ϫ457 domain (data not shown). These results are consistent with a ubiquitous, proximal positively acting domain between CYP4B1 position Ϫ139 and Ϫ45, a liver-selective negatively acting domain between CYP4B1 position Ϫ457 and Ϫ216, and a lung-selective positively acting domain between CYP4B1 position Ϫ1087 and Ϫ457.
A series of reporter constructs in which CYP4B1 sequences from position Ϫ1087 to ϩ35, Ϫ1006 to ϩ35, Ϫ890 to ϩ35, Ϫ749 to ϩ35, Ϫ660 to ϩ35, and Ϫ457 to ϩ35 directed luciferase expression were utilized for transient expression assays in A549 cells to further define the location of the distal, lung-selective CYP4B1 regulatory element. No increase in reporter gene activity over that seen with the proximal regulatory element was observed with constructs that included CYP4B1 sequences up to position Ϫ1008 (pRNH833) (Fig. 3) . However, a significant increase was observed when sequences up to position Ϫ1087 were included. These data indicated the distal regulatory element resides between CYP4B1 position Ϫ1087 to Ϫ1008. Regulation by the Proximal CYP4B1 Positive Regulatory Domain Involves Sp/XKLF Factors. EMSA was used to assess whether or not specific DNA/protein interactions were possible within the proximal CYP4B1 positive regulatory domain (position Ϫ138 to Ϫ46). Using A549 cell nuclear protein extract, five DNA/protein complexes were observed, three of which represented specific DNA/ protein interactions based on competition with unlabeled probe DNA (Fig. 4, complexes A, B , and C, compare lanes 2 and 3). Analysis of the CYP4B1 sequences from position Ϫ138 to Ϫ46 using the Match program in conjunction with the TRANSFAC V 8.3 Professional database revealed six strong matches to the consensus binding site for the Sp/XKLF family of transcription factors (Fig. 5) . Consistent with this observation, competitive EMSA using a 100-fold molar excess of a consensus Sp/XKLF sequence (Table 1 ) resulted in the elimination of all three specific DNA/protein complexes (Fig. 4, complexes A, B , and C, compare lanes 2 and 4). Supershift EMSA was used to determine which of the Sp/XKLF factors might be involved in specifically binding the CYP4B1 proximal regulatory element. Inclusion of an Sp1-monospecific antibody in the DNA/protein binding reaction resulted in a supershift of complex B (Fig. 4, lane 5) , whereas the addition of an Sp3-monospecific antibody resulted in a supershift of both complexes A and C (Fig. 4, lane 6) . Addition of both antibodies resulted in a supershift of all three specific DNA/protein complexes (Fig. 4, lane 7) . Thus, these data strongly implicate a role for Sp1 and/or Sp3 in regulating CYP4B1 expression through the proximal regulatory element.
Cotransfection of A549 cells with both the CYP4B1-directed reporter constructs and Sp1 or Sp3 expression vectors was used to (Fig. 6) . Neither Sp1 nor Sp3 had any impact on the background reporter activity observed with the promoterless pGL3basic reporter vector. Cotransfection with the pRNH698 reporter construct (CYP4B1 position Ϫ138 to ϩ30 directing luciferase expression) and either an Sp1 or Sp3 expression vector resulted in a 3-fold increase in promoter activity relative to that observed with a blank expression vector (Fig.  6A) . Cotransfection with the pRNH686 reporter construct (CYP4B1 position Ϫ1087 to ϩ30 directing luciferase expression) and the Sp1 expression vector resulted in a 5-fold increase in reporter activity. In contrast, cotransfection with pRNH686 and the Sp3 expression vector had no effect on luciferase activity (Fig. 6B) . Similar cotransfection experiments in HepG2 cells also resulted in a 5-fold increase in activity with the pRNH686 reporter construct (data not shown).
Sp1/Sp3 binding to the proximal regulatory domain in vivo was determined using ChIP analysis along with the same cells lines in which transient expression assays were performed (A549, HepG2, and BEAS-2B cells) and autopsy samples of liver and lung tissue. The CYP4B1 proximal regulatory domain was bound by Sp1, but not Sp3, in HepG2 cells (Fig. 7A) . In contrast, both Sp1 and Sp3 were observed to bind the proximal regulatory domain in A549 cells with Sp1 in excess of Sp3, whereas in BEAS-2B cells, both Sp1 and Sp3 bound, but Sp3 was in excess of Sp1. Binding appeared much less robust in the latter cell line. A different situation was observed in the lung and liver tissue samples. The CYP4B1 proximal regulatory domain was bound by Sp1 in lung tissue, but not liver (Fig. 7B) , whereas Sp3 binding was not observed in either tissue. These latter results contrast to what was observed with the CYP2F1 basal promoter using these same antibodies and tissue samples in which Sp1 binding was observed in lung, but not liver, whereas Sp3 binding was observed in liver, but not lung (Wan et al., 2005) .
Given that six putative Sp/XKLF sites were identified in the proximal element (Fig. 5) , competitive EMSA was used to determine which of these sites might be responsible for the observed specific DNA/protein interactions and functional impact on the CYP4B1 promoter. Double-stranded oligonucleotides incorporating site 1, sites 3/4, and site 6 failed to compete at even a 300-fold molar excess (Fig.  8, lanes 5-7) . In contrast, concentration-dependent competition was observed with the double-stranded oligonucleotide incorporating the site 2-putative Sp/XKLF element (CYP4B1 position Ϫ128 to Ϫ105; Fig. 8, lanes 8 -10) . Although not as strong, concentration-dependent competition also was observed with the double-stranded oligonucleotide incorporating the putative site 5 element (CYP4B1 position Ϫ87 to Ϫ59; Fig. 8, lanes 11-13) . Consistent with these results, mutagenesis of sites 2 and 5 from 5Ј-CCGCC-3Ј to 5Ј-TTGCC-3Ј within the CYP4B1 Ϫ138 to Ϫ46 fragment, although leaving sites 1, 3, and 4, and 6 intact, eliminated the ability of this fragment to compete for specific DNA/protein binding (Fig. 8, lanes 14 and 15) .
To validate the activity of Sp/XKLF sites 2 and 5 identified by competitive EMSA, site-directed mutagenesis was used to eliminate 
Downloaded from
Sp1/Sp3 binding at these elements within the CYP4B1 reporter constructs. The same base changes made within Sp/XKLF site 2 (CYP4B1 position Ϫ118 to Ϫ114) and/or Sp/XKLF site 5 (CYP4B1 position Ϫ77 to Ϫ73) that eliminated specific DNA/protein binding (Fig. 8) were introduced into pRNH698 (CYP4B1 position Ϫ139 to ϩ35 directing luciferase expression) and pRNH686 (CYP4B1 position Ϫ1087 to ϩ35 directing luciferase expression) resulting in pRNH844 and 838 (site 2 mutagenized), pRNH845 and 842 (site 5 mutagenized), and pRNH846 and 843 (sites 2 and 5 mutagenized), respectively. The impact of these changes on CYP4B1-directed luciferase expression was examined after transient transfection into A549 cells (Fig. 9) . When examined within the context of the proximal regulatory element alone (CYP4B1 position Ϫ139 to Ϫ45), an approximate 2-fold loss in promoter activity was observed with the elimination of site 2 (pRNH844 versus 698, p Ͻ 0.05) or site 5 (pRNH845 versus 698, p Ͻ 0.001) alone. However, mutagenesis of both sites 2 and 5 resulted in a complete loss of promoter activity (pRNH846 versus 698, p Ͻ 0.001; pRNH846 versus pGL3basic, p Ͼ 0.05).
Loss of Sp1/Sp3 binding at the proximal regulatory element also had a substantial impact on the function of the lung-selective distal regulatory element (CYP4B1 position Ϫ1087 to Ϫ1008) (Fig. 8) . Elimination of either Sp/XKLF site 2 or site 5 by itself within the context of both the proximal and distal elements decreased CYP4B1 promoter activity by 1.5-(pRNH838 versus 686, p Ͻ 0.01) or 3-fold (pRNH842 versus 686, p Ͻ 0.001), respectively. The reporter vector pRNH846 with both Sp/XKLF sites 2 and 5 mutagenized decreased the reporter activity 5-fold (pRNH843 versus 686, p Ͻ 0.001) but to a level that remained 2-fold above that observed with the promoterless vector (pRNH843 versus pGL3Basic, p Ͻ 0.001).
Further Characterization of the Distal CYP4B1 Regulatory Element. To evaluate specific protein binding within the CYP4B1 distal, lung-selective regulatory element, EMSAs were performed using CYP4B1 sequences from position Ϫ1087 to Ϫ1008 as a probe along with nuclear protein extract prepared from A549 cells. A single specific DNA/protein complex was observed, as demonstrated by the ability of a 50-fold molar excess of unlabeled DNA probe to eliminate binding to the radiolabeled DNA probe. Competition with two overlapping double-stranded oligonucleotides further localized the domain responsible for specific binding to CYP4B1 sequences position Ϫ1052 to Ϫ1008 (data not shown). Using CYP4B1 sequences from Ϫ1052 to Ϫ1008 as an EMSA probe, two major and one minor specific DNA/ protein complexes were observed (Fig. 10, complexes A, B , and C, compare lane 2 with lanes 3 and 4). Competition with a 100-fold molar excess of an oligonucleotide representing CYP4B1 position Ϫ1052 to Ϫ1026 eliminated specific DNA/protein complex C, but not A or B (Fig. 10, lane 5) . In contrast, an oligonucleotide representing CYP4B1 position Ϫ1042 to Ϫ1008 failed to compete for specific binding (Fig. 10, lane 6) . When repeated using HepG2 nuclear extract, specific DNA protein interactions were not observed with the CYP4B1 position Ϫ1052 to Ϫ1008 probe. These observations are consistent with two binding domains between position CYP4B1 position Ϫ1052 and Ϫ1042 and position Ϫ1026 and Ϫ1008 in which binding to the upstream site is obligatory for subsequent binding to the downstream site. Furthermore, these DNA/protein interactions appear lung-selective.
Analysis of the CYP4B1 distal regulatory element position Ϫ1052 to Ϫ1008 using the Match program in conjunction with the TRANS-FAC V 8.3 Professional database revealed strong matches for putative AP-4, Elk-1, C/EBP, and HNF3 sites. Competitive EMSA was used to identify which, if any, of the identified factors were capable of specifically binding the CYP4B1 lung-selective distal element. However, competition was not observed using a 150-fold molar excess of known consensus binding sequences for AP-4 (Fig. 10, lane 7) , C/EBP (Fig. 10, lane 8) , Elk-1 (Fig. 10, lane 9) , or HNF3 (Fig. 10,  lane 10 ). In addition, antibodies for AP-4, Elk-1, C/EBP␣, C/EBP␤, C/EBP␦, and C/EBP␥ failed to shift the mobility of any of the specific DNA/protein complexes observed with the CYP4B1 position Ϫ1052 to Ϫ1008 probe (data not shown). Finally, cotransfection with pRNH686 and AP-4, C/EBP␣, or C/EBP␤ expression vectors failed to alter reporter activity (data not shown).
Discussion
This investigation used CYP4B1 as a model system to examine lung-selective mechanisms controlling cytochrome P450 expression. Three major regulatory elements were identified, a proximal positive FIG. 7 . ChIP assay of Sp1 and Sp3 binding to the CYP4B1 proximal regulatory region in lung and liver tissues and specific cell lines. ChIP assays were performed as described under Materials and Methods using (A) tissue from lung or liver autopsy samples and (B) A549, HepG2, or BEAS-2B cell lines. Immunoprecipitation was done with either Sp1 or Sp3 antibodies, and the isolated chromatin examined for enrichment of CYP4B1 sequences from position Ϫ241 to ϩ20 by PCR. Amplified DNA was fractionated by agarose gel electrophoresis and visualized by ethidium bromide staining. The mobility of included molecular size standards is indicated to the left of each photo.
regulatory element located between CYP4B1 position Ϫ118 and Ϫ73 that involves Sp1 and/or Sp3 binding at two sites, a liver-selective negative regulatory element located between CYP4B1 position Ϫ457 and Ϫ216, and a distal, lung-selective positive element located between CYP4B1 position Ϫ1052 and Ϫ1008 that involves as yet unidentified transcription factor(s). Although the in vitro DNA/protein binding assays and the transient expression data are consistent with both Sp1 and Sp3 regulating CYP4B1 in a tissue-nonselective fashion, the in vivo ChIP data implicates the selective binding of Sp1 to the CYP4B1 proximal promoter element in lung tissue and as such, is consistent with the conclusion that the proximal regulatory element also contributes to CYP4B1 lung-selective expression.
A Match analysis of the proximal CYP4B1 element using the TRANSFAC Professional v 8.3 database identified six potential Sp/ XKLF binding sites. However, only two of the sites appear to be functional (CYP4B1 position Ϫ118 to Ϫ114 and Ϫ77 to Ϫ73), both capable of binding the Sp/XKLF family members Sp1 and Sp3 and responding to both factors in transient expression assays. Sp1 and Sp3 are ubiquitously expressed, consistent with the observation that the CYP4B1 proximal element functioned equally well in both lung-and liver-derived cells. These latter data also are consistent with the inability of the lung-selective member of the Sp/XKLF family, the lung Krüppel-like factor (LKLF) (Anderson et al., 1995) , to modulate the activity of the proximal element. Major differences between Sp1 and Sp3 lie with the ability of Sp1, but not Sp3, to form multimeric complexes and in doing so, synergistically up-regulate promoter activity (Su et al., 1991; Yu et al., 2003) . In addition, the Sp1 inhibitory domain is located at the N terminus of the protein, whereas in Sp3 it is located next to the three conserved Cys 2 His 2 zinc fingers involved in DNA binding (Suske, 1999) . These differences in functional motifs permits Sp3 to commonly function as a repressor, although instances also exist where it serves as a strong, positively acting factor (Sowa et al., 1999; Rao et al., 2002) . In the case of the CYP4B1 proximal element, Sp1 and Sp3 can compete for binding in vitro and both work to positively regulate promoter activity in the transient expression assays. However, Sp1 results in a more robust response.
Within the context of the proximal regulatory element alone, the mutagenesis studies suggest the two CYP4B1 proximal Sp1/Sp3 sites act in a largely additive and independent fashion. Thus, Sp/XKLF site 5 enhanced promoter activity 1.4-fold (Fig. 9, pRNH844 versus 698) , whereas Sp/XKLF site 2 enhanced activity 2.1-fold (Fig. 9, pRNH845  versus 698 ). Together, a 3.7-fold enhancement was observed (Fig. 9 , pRNH846 versus 698), essentially equal to the predicted additive response of 3.5-fold. In contrast, when examined in the context of the FIG. 8 . Putative Sp/XKLF sites 2 and 5 within the CYP4B1 position Ϫ139 to Ϫ45 proximal regulatory domain are capable of specific protein binding. The ability of each of the putative Sp/XKLF sites within the CYP4B1 proximal positive regulatory domain to specifically bind A549 nuclear protein was examined by competitive EMSA with double-stranded oligonucleotides representing each site. EMSA was performed as described under Materials and Methods. Specific DNA/protein complexes (A, B, and C in order of increasing electrophoretic mobility) are indicated by the solid arrows to the left of the autoradiogram. Competition was performed with a 50-to 300-fold molar excess of overlapping, double-stranded oligonucleotides representing CYP4B1 positions Ϫ138 to Ϫ46 (lanes 3-4), Ϫ142 to Ϫ119 (lane 5), Ϫ112 to Ϫ76 (lane 6), Ϫ72 to Ϫ48 (lanes 7), Ϫ128 to Ϫ105 (lanes 8 -10), and Ϫ87 to Ϫ59 (lanes 11-13). In addition, competition with an oligonucleotide having the Sp/XKLF sites mutagenized at CYP4B1 positions Ϫ118 to Ϫ114 (site 2) and Ϫ77 to Ϫ73 (site 5) is shown (lanes 14 -15).
full-length promoter, an enhancement somewhat greater than the predicted additive response was observed, i.e., a 5.2-fold enhancement (Fig. 9, pRNH843 versus 686) versus a predicted 4.3-fold additive response (Fig. 9 , pRNH842 versus 686 and pRNH838 versus 686). Although these data are not convincing alone, synergism also is apparent in experiments where Sp1 or Sp3 expression vectors were cotransfected with CYP4B1/luciferase reporter constructs. These data showed that both Sp1 and Sp3 were able to further enhance promoter activity in the context of the proximal promoter alone. In contrast, Sp3 had no impact when overexpressed in the presence of the full-length construct, whereas cotransfection with the Sp1 expression vector resulted in a further 5-fold increase in promoter activity. Thus, the ability of Sp1 to form multimeric complexes involving multiple sites and synergistically activate transcription through protein-protein interactions has a minimal impact on the proximal promoter element alone but does function in the context of both the proximal and lung-selective distal element.
Cooperativity between Sp1 and lung-selective, as well as other tissue-selective, transcription factors has been documented (reviewed in Li et al., 2004) . In this context, tissue-specific regulation involves the specific cellular environment, relative Sp1 and Sp3 expression levels, and protein modification. Thus, a significantly higher level of Sp1 was found in thymus, lung, and spleen tissue than was found in other tissues, including the liver (Saffer et al., 1991) . Variation in Sp1/Sp3 ratios impacted cell-specific regulation of the kinase domain receptor in endothelial cells (Hata et al., 1998) , the HPV-16 promoter in epithelial cells (Apt et al., 1996) , and the COL2A1 promoter in chondrocytes (Chadjichristos et al., 2002) . Protein modification of Sp1 and Sp3, including phosphorylation, glycosylation, sumoylation, and acetylation may also contribute to the cell-specific expression of a variety of proteins. Finally, a role for Sp1 and Sp3 in regulating the lung-selective expression of another cytochrome P450, i.e., CYP2F1, has recently been documented (Wan et al., 2005) . The importance of Sp1 in regulating CYP4B1 lung-selective expression is apparent from the combined in vitro and in vivo studies presented in the current study and likely involves one or more of the above control mechanisms.
Tissue-selective CYP4B1 expression also is controlled by the combined effect of the lung-selective distal regulatory element localized between position Ϫ1052 to Ϫ1008 and the absence of regulation through the liver-selective negative regulatory element localized between position Ϫ457 and Ϫ216. Although the importance of the negative regulatory element is apparent by the marked decrease in reporter activity observed in transient expression assays with HepG2 cells, results with the 293 kidney-derived cell line would suggest a greater importance of the combinatorial regulation observed between the proximal and distal positively-acting elements. A more complete assessment of the negative element's impact on CYP4B1 lung-specific expression will require a more exhaustive analysis of cell lines in which CYP4B1 is not expressed. Regulation through the CYP4B1 distal domain appears to involve transcription factor(s) binding to both CYP4B1 positions Ϫ1052 to Ϫ1042 and Ϫ1026 to Ϫ1008 but appears to require binding at the upstream site for subsequent binding to the downstream site. Although a search of the CYP4B1 distal regulatory element with Match using the TRANSFAC database suggested potential roles for several transcription factors known to be involved in lung-selective regulation, competitive DNA binding, antibody supershift experiments, and transient reporter assays with transcription factor expression vectors eliminated all of these potential candidates. Identification of this unknown lung-specific regulatory factor(s) will require further study.
In summary, Sp1 acting through a proximal enhancer element and in combination with a distal, lung-selective enhancer, is critical for CYP4B1 lung-selective regulation. Also contributing to CYP4B1's tissue-selective expression pattern is a liver-selective repressor motif. Although the activity of the human CYP4B1 protein is controversial (Imaoka et al., 2001; Zheng et al., 2003) , studies have demonstrated CYP4B1 expression at the level of mRNA in lung tissue. Such lung-selective expression is distinctive and worthy of the mechanistic investigation reported herein. Thus, the current data contribute substantially to our understanding of the molecular mechanisms controlling cytochrome P450 lung-selective expression.
